STING1 and cancer: Future efforts must map spatiotemporal control of this axis across human cancers, engineer accurate strategies to modulate mtDNA leakage and STING activity, integrate nanotechnology-based delivery systems with combinatorial immunotherapies, and rigorously validate safety and efficacy, thereby accelerating the clinical translation of personalized cancer immunotherapy.